Free Trial
LON:EDGI

Edge Performance VCT Public (EDGI) Share Price, News & Analysis

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)
Free EDGI Stock Alerts
Compare
Today's Range
N/A
50-Day Range
4
▼
4
52-Week Range
N/A
Volume
34,422 shs
Average Volume
27,400 shs
Market Capitalization
£3.39 million
P/E Ratio
0.37
Dividend Yield
297.25%
Price Target
N/A
Stock Analysis
Stock Analysis

About Edge Performance VCT Public

Edge Performance VCT Public Limited Company is a venture capital trust specializing in investments in early venture and growth capital investments. It invests in creative industries and the technologies which enable it. The fund invests in media and entertainment sectors concentrating on companies that promote live music, theatre, sports, festival trade shows, exhibitions and other similar events. It seeks to invest in companies based primarily in the United Kingdom. The average holding period is five years.

EDGI Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive EDGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edge Performance VCT Public and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Finance
Industry
Asset Management
Sub-Industry
N/A
Current Symbol
LON:EDGI
CUSIP
N/A
CIK
N/A
Web
www.edge.uk.com
Phone
44 20 7317 1300
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
0.37
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
91.88
Quick Ratio
91.88

Sales & Book Value

Annual Sales
£9.72 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
0.98
Book Value
GBX 21.30 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
84,696,000
Free Float
N/A
Market Cap
£3.39 million
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. David Glick (Age 58)
    Founder, Chief Exec. Officer and Independent Director
    Comp: $15k
  • Mr. Steven Carle
    Chief Investment Officer

Key Competitors

View All Competitors

EDGI Stock Analysis - Frequently Asked Questions

Is Edge Performance VCT Public a good dividend stock?

Edge Performance VCT Public (LON:EDGI) pays an annual dividend of GBX 0.09 per share and currently has a dividend yield of 297.25%. EDGI has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 0.79%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for EDGI.

How do I buy shares of Edge Performance VCT Public?

Shares of EDGI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:EDGI) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners
These AI trades triggered this morning (545% return)
Prosper Trading Academy
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
Banyan Hill Publishing
He Is Giving Away Bitcoin
Crypto Swap Profits
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Biden out June 13; Kamala won’t replace him?
Paradigm Press
Fed launches fourth dollar overhaul
Stansberry Research
The World's First "$20 Trillion Drug?"
Behind the Markets